Nyxoah Ltd.

www.nyxoah.com

High-Tech Company
Public Company

(NASDAQ GM: NYXH), (Euronext Brussels: NYXH)

TECH VERTICALS

Healthtech, Life Sciences, Medical Devices, MedTech, Neuroscience

General Data

Sector	Medical Devices
Company Stage:	Revenue Growth
Established	2009
Number of Employees	188
Employees in Israel	30
Reg. Number:	abCDe

DESCRIPTION

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).

Nyxoah’s lead solution platform is based on the Genio® system, an FDA approved and CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk* and comorbidities including cardiovascular diseases, depression and stroke.

TECHNOLOGY

Nyxoah’s lead solution platform is based on the Genio® system, a validated, user-centered next generation neurostimulation therapy for Obstructive Sleep Apnea.

Products and Phases

Product	Phase
Genio®	FDA Approved CE Approved
Genio® system is a validated, user-centered next generation neurostimulation therapy for Obstructive Sleep Apnea.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Obstructive Sleep Apnea (OSA) market.

	BUSINESS MODEL
	B2B

REMARKS

Date

Remark

03/07/2024

Nyxoah announced that it has signed a €37.5m loan facility agreement with the European Investment Bank (“EIB”). Nyxoah plans to use the funding for research and development, and for scaling-up its manufacturing capacity to meet demand in Europe and the U.S. The €37.5m facility is divided into three tranches: €10m for the first tranche, €13.75m for the second tranche and €13.75m for the third tranche.

CONTACT INFO

Expand / Collapse All

Main Address: Mont-Saint-Guibert, Belgium

Address	Rue Edouard Belin 12
City	Mont-Saint-Guibert
Country	Belgium
Zip	1435

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Tel Aviv, Israel

Address	126 Igal Alon St.
City	Tel Aviv
Country	Israel
Zip	6744332

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Olivier Taelman	CEO
Mr. Bruno Onkelinx	CTO
Mr. Remi Renard	Chief of Staff
Mr. Roi Tsukran	VP, R&D
Mr. Robert Taub	Co-Founder
Dr. Adi Mashiach	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Executive Chairman	Co-Founder, Nyxoah
abC Defghij	Vice Chairman	General Partner, Gilde Healthcare
abC Defghij	Board Member	Vice Rector, Université catholique de Louvain
abC Defghij	Board Member	Co-founder, HighCape Partners
abC Defghij	Board Member	CEO, FemPulse
abC Defghij	Board Member	CTO, Cochlear

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
May. 28, 2024	Fifth Public Offering	NASDAQ GM	abCDe	abCDe	$2.5m from exercised greenshoe option to purchase additional shares by the underwriters.
Apr. 13, 2023	Fourth Public Offering	NASDAQ GM	abCDe	abCDe	The shares were purchased by shareholder Cochlear Limited pursuant to the Company’s $50 million at-the-market ("ATM") program established on December 22,.2022.
Mar. 27, 2023	Third Public Offering	NASDAQ GM	abCDe	abCDe	The shares were purchased by shareholder Cochlear Limited pursuant to the Company’s $50 million at-the-market ("ATM") program established on December 22,.2022.
Jul. 07, 2021	Second Public Offering	NASDAQ GM	abCDe	abCDe	$12.7m from the underwriters' exercised option to purchase additional shares (green shoe options).
Sep. 29, 2020	IPO	Euronext Brussels	abCDe	abCDe	Raised EUR 85m, Valuation EUR 375m

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Mar. 23, 2023

Initial Revenues

abCDe

€13.35

* New investor

Investor	Type	Amount	Remarks
abC Defghij	High-Tech Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe

Fifth Round

Feb. 12, 2020

R&D

abCDe

Raised EUR 25m

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	High-Tech Company	abCDe	Led the round
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Fourth Round

Nov. 12, 2018

R&D

abCDe

15m EUR

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	High-Tech Company	abCDe	13m EUR; Led the round
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Third Round

Jul. 04, 2016

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Investment Company	abCDe	Provided a loan.
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Second Round

May. 21, 2014

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Venture Capital Fund	abCDe	Led the round
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

First Round

Aug. 01, 2012

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe	Led the round
abC Defghij	Private Investor	abCDe

Last Updated:	abCDe
IVC Number:	abCDe